Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

Prostate

Volumn 35, Issue 1, 1998, Pages 1-10

  Borgström, Per ^a   Bourdon, Mario A ^b   Hillan, Kenneth J ^b   Sriramarao, P ^b   Ferrara, Napoleone ^c  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b La Jolla Institute for Experimental Medicine   (United States)

^c GENENTECH INC   (United States)

Author keywords

Angiostatic; Anti angiogenic; Human; Intravital microscopy; Prostate; Skinfold; Tumor spheroid; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; FLUORESCENT DYE; MONOCLONAL ANTIBODY A 4 6 1; NEUTRALIZING ANTIBODY; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ENDOTHELIAL GROWTH FACTORS; FLUORESCENT DYES; HUMANS; LYMPHOKINES; MALE; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0031898292     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980401)35:1<1::AID-PROS1>3.0.CO;2-O     Document Type: Article

References (22)

1. Mettlin C, Jones GW, Murphy GP: Trends in prostate cancer care in the United States, 1974-1990: Observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin 1993;43:83-91.
2. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retro-pubic prostatectomy: Results at 10 years. J Urol 1994;152:1831-1836.
3. Catalona WJ, Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-1842.
4. Hanks GE, Hanlon A, Schultheiss T, Corn B, Shipley WU, Lee WR: Early prostate cancer: The national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. J Urol 1994;152:1775-1780.
5. Bagshaw MA, Cox RS, Hancock SL: Control of prostate cancer with radiotherapy: Long-term results. J Urol 1994;152:1781-1785.
6. Optenberg SA, Thompson IM: Economics of screening for carcinoma of the prostate. Urol Clin North Am 1990;17:719-737.
7. Weidner N, Caroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
8. Ichikawa T, Lamb JC, Christensson PJ, Harley-Asp B, Isaacs JT: The antitumor effects of the quinoline-3-carboxamidelinomide on Dunning R-3327 rat prostatic cancers. Cancer Res 1992;52: 3022-3028.
9. Vukanovic J, Isaacs JT: Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 1995;55:1499-1504.
10. Vukanovic J, Hartley-Asp B, Isaacs JT: Inhibition of tumor angiogenesis and the therapeutic ability of Linomide against rat prostatic cancers. Prostate 1995;26:235-246.
11. Kim JK, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362:841-844.
12. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
13. Borgström P, Hillan KJ, Sriramarao P, Ferrara N: Complete inhibition of angiogenesis and growth of micro tumors by an anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032-4039.
14. Joseph IBJK, Isaacs JT: I Potentiation of the antiangiogenic ability of Linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 1997;57:1054-1057.
15. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K: Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 1996;74:910-916.
16. Lehr H, Leunig M, Menger MD, Messmer K: Dorsal skinfold chamber technique for intravital microscopy on striated muscle in nude mice. Am J Pathol 1993;43:1055-1062.
17. Leunig M, Yuan F, Menger MD, Boucher Y, Goetz AE, Messmer K, Jain RK: Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992;52:6553-6560.
18. Borgström P, Sriramarao P, Hillan KJ, Ferrara N: Combination treatment with monoclonal anti-VEGF antibody and doxorubicin reduces size of micro tumors of human breast carcinoma in vivo. Proc AACR 1997;38 (abst 3524).
19. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N: Regulation of vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-1797.
20. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR: Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992;3:211-220.
21. Raghaven D: Non-hormone chemotherapy for prostatic cancer. N Engl J Med 1989;321419-424.
22. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T: Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 1993;53:5233-5236.